Study Design

INA-PROACTIVE was a multicenter, prospective, observational cohort study of HIV-positive antiretroviral-naĂŻve and treatment-experienced individuals. No investigational treatment or intervention was used in this study. All participants were managed according to the Indonesian HIV/AIDS Treatment Guideline and the Standard of Care (SoC) in the local clinical setting, with the addition of rapid HIV viral load, CD4 cell count, and syphilis testing.

Data were collected on all participants at baseline and follow-up visits every 6 months (±3-month window period). Additional follow-up data were collected on selected participants who met additional study follow-up criteria.

Subject Characteristics

In this report, the focus was on analyzing pediatric patients. Initially, there were 189 pediatric patients under consideration. However, after careful evaluation, six pediatric patients were excluded from the analysis. These exclusions were based on the presence of certain risk factors associated with acquiring HIV, including engaging in heterosexual or homosexual behaviors, being recipients of blood products. These criteria were applied to ensure a more homogeneous study population for accurate analysis and interpretation of the data.

Those patients are:
ID_patients Reason
1045601008 Blood product recipient
1045701004 Homosexual
1046301006 Homosexual
1046801001 Heterosexual
1046901004 Heterosexual

In this section, table characteristics is shown for subject characteristics at Enrollment PROACTIVE study.

Characteristics N, %
Gender
Male 87 (47.3%)
Female 97 (52.7%)
Sites
510 10 (5.4%)
520 5 (2.7%)
530 36 (19.6%)
540 20 (10.8%)
550 10 (5.4%)
560 11 (5.9%)
570 5 (2.7%)
580 4 (2.2%)
590 10 (5.4%)
600 2 (1.1%)
610 17 (9.2%)
630 8 (4.3%)
650 4 (2.2%)
660 17 (9.2%)
670 5 (2.7%)
680 7 (3.8%)
690 3 (1.6%)
700 10 (5.4%)
Birth History:
Delivery method:
Vaginal 133 (72.3%)
Caesarian 39 (21.2%)
Elective 22 (12.0%)
Non-Elective 17 (9.2%)
Birth weight:
< 2500 gram 11 (7.8%)
2500-3000 gram 63 (45.7%)
>3000 gram 64 (46.4%)
Neonatal status 172 (93.5%)
full term 165 (89.7%)
pre-term 7 (3.8%)
Birth defect: (n=X) 1 (0.5%)
Mother with antenatal care/ ANC History 137 (74.5%)
Mother with ARV during pregnancy 2 (1.1%)
Mother with ARV during delivery 4 (2.2%)
Exclusive breastfed 134 (72.8%)
Prophylaxis ARV
Age (months):
At diagnosis: 43.4 (1.0 - 206.0)
At treatment: 51.1 (0.0 - 207.0)
At enrollment: 101.6 (15.0 - 210.0)
Diagnosis methods:
Rapid diagnostic tests 79 (42.9%)
ELISA 15 (8.15%)
PCR DNA 1 (0.5%)
PCR RNA 3 (1.6%)
Rapid and ELISA 18 (9.8%)
Rapid and PCR DNA 1 (0.5%)
First time HIV was diagnosed:
<2015: 86 (46.7%)
2015-2017 47 (25.5%)
2018-2019 23 (12.5%)
Reasons for HIV tests:
Own initiative: n (reasons) 9 (4.9%)
Advised by Health Providers: 169 (91.8%)
Opportunistic infection: 49 (28.9%)
Positive mothers: 71 (41.0%)
Non-responsive malnutrition children: 3 (1.8%)
Others: 46 (27.2%)
Tuberculosis history:
Pulmonary tuberculosis: 71 (38.6%)
Extra-pulmonary tuberculosis: 11 (5.9%)
CD4 testing
At diagnosis:
In percentage: (n=X)
>30% 13 (7.1%)
25-30% 9 (4.9%)
15-25% 26 (14.1%)
<15% 34 (18.5%)
In absolute
>500 72 (39.1%)
350 - 500 18 (9.8%)
200 - 350 19 (10.3%)
<200 43 (23.4%)
At treatment:
In percentage (n=Y)
>30% 34 (18.5%)
25-30% 20 (10.9%)
15-25% 21 (11.4%)
<15% 18 (9.8%)
In absolute:
>500 117 (63.6%)
350 - 500 12 (6.5%)
200 - 350 11 (5.9%)
<200 26 (14.1%)
At enrollment:
In percentage (n= Z)
>30% 15 (8.15%)
25-30% 16 (8.7%)
15-25% 16 (8.7%)
<15% 12 (6.5%)
In absolute:
>500 99 (53.8%)
350 - 500 16 (8.7%)
200 - 350 15 (8.15%)
<200 19 (10.3%)
Viral load testing: (<10,000; 10K-100K, >100K)
At diagnosis:
<10.000 36 (19.6%)
10K - 100K 22 (12.0%)
>100K 49 (26.6%)
At treatment:
<10.000 46 (25.0%)
10K - 100K 23 (12.5%)
>100K 41 (22.3%)
At enrollment:
<10.000 22 (12.0%)
10K - 100K 23 (12.5%)
>100K 37 (20.1%)
Clinical diagnosis:
At diagnosis:
1 31 (16.8%)
2 29 (15.8%)
3 92 (50.0%)
4 21 (11.4%)
Unknown 11 (5.9%)
At treatment:
1 32 (17.4%)
2 29 (15.8%)
3 92 (50.0%)
4 21 (11.4%)
Unknown 10 (5.4%)
At enrollment:
1 80 (43.5%)
2 24 (13.0%)
3 61 (33.2%)
4 17 (9.3%)
Unknown 2 (1.1%)
Family Medical History (father, mother, sibling)
HIV
Father 110 (60.1%)
Mother 173 (94.5%)
Siblings 19 (10.4%)
Pulmonary tuberculosis
Father 38 (24.5%)
Mother 34 (21.9%)
Siblings 8 (5.2%)
Diabetes
Father 1 (0.5%)
Mother 0 (0.0%)
Siblings 0 (0.0%)
ARV history:
NaĂŻve
Duration between diagnosis and treatment Initial regimens: 9 (4.9%)
0-6 months on ARV
Duration between diagnosis and treatment Initial regimens: 14 (7.6%)
Switching regimens: 3 (21.4%)
6 months – 1 year on ARV
Duration between diagnosis and treatment Initial regimens: 10 (5.4%)
Switching regimens: 2 (20.0%)
>1 year on ARV
Duration between diagnosis and treatment Initial regimens: 151 (82.1%)
Switching to 2nd line: 41 (27.2%)

Plots

Plot Naive, Experience Group

  • The “Naive group” includes individuals who have never undergone ART treatment.
  • The “Experience group” consists of those who have received ART treatment for at least one day.
  • Enrollment date serves as the baseline for counting the duration until the first ARV treatment for individuals in both groups.
Naive_experience <- read_excel("Naive_experience.xlsx")

ggplot(Naive_experience, aes(x=Var1, y=Freq, fill=Var1)) + 
  geom_bar(stat = "identity") + 
  theme_minimal() +
  ggtitle("Naive, Experience Group") +
  xlab("ARV Treatment Groups") +
  scale_x_discrete(labels=c( "1" = "<6 months",
                            "2" = "6-12 months", "3"=">12months")) +
  geom_text(aes(label = Freq), vjust = -0.3, size = 3.5) +
  scale_fill_manual(name = "", labels = c("<6 months", "6-12 months",">12months"),
                    values = c("#22A884FF","#7AD151FF", "#440154FF"))

Plot Alive and LTFU Vs ARV Treatment

  • The “LTFU” group comprises individuals who were lost to follow up during the study period.
  • The “Alive” group consists of individuals who survived until the end of the study.
  • The “Death” group includes individuals who died during the study period.
LTFU_Alive <- read_excel("LTFU_Alive.xlsx")
ggplot(LTFU_Alive, aes(fill=Var1, y=Freq, x=Var2, label=Freq)) + 
  geom_bar(position="stack", stat="identity") +
  geom_text(size = 3, position = position_stack(vjust = 0.5))+
  ggtitle("LTFU, Alive Vs ARV Treatment") +
  theme_minimal() +
  xlab("ARV Treatment Groups") +
  scale_x_discrete(labels=c("1" = "<6 months",
                            "2" = "6-12 months", "3"=">12months")) +
 scale_fill_manual(name = "", labels = c("Alive","Death","LTFU"), 
                   values = c("#404688FF","#FDE725FF","#75D054FF"))
## Warning: Removed 2 rows containing missing values (`position_stack()`).
## Removed 2 rows containing missing values (`position_stack()`).

Survival Analysis

Survival Analysis Duration ART Treatment

Survival analysis was conducted among individuals categorized into four groups based on the duration of antiretroviral therapy (ART) treatment: naive, <6 months, 6 to 12 months, and >12 months.

fit1 <- survfit(surv_object ~ Categories, data = Surv_ENR)
summary(fit1)
## Call: survfit(formula = surv_object ~ Categories, data = Surv_ENR)
## 
##                 Categories=1 
##      time n.risk n.event survival std.err lower 95% CI upper 95% CI
## 
##                 Categories=2 
##         time       n.risk      n.event     survival      std.err lower 95% CI 
##     819.0000      13.0000       1.0000       0.9231       0.0739       0.7890 
## upper 95% CI 
##       1.0000 
## 
##                 Categories=3 
##      time n.risk n.event survival std.err lower 95% CI upper 95% CI
## 
##                 Categories=4 
##  time n.risk n.event survival std.err lower 95% CI upper 95% CI
##    43    151       1    0.993  0.0066        0.981        1.000
##   274    150       1    0.987  0.0093        0.969        1.000
##   383    149       1    0.980  0.0114        0.958        1.000
##   392    148       1    0.974  0.0131        0.948        0.999
##   518    146       1    0.967  0.0146        0.939        0.996
##   552    145       1    0.960  0.0159        0.929        0.992
##   567    144       1    0.954  0.0172        0.920        0.988
##   708    143       1    0.947  0.0183        0.912        0.983
ggsurvplot(fit1, data = Surv_ENR, pval = TRUE, xlab="Duration of Study (Days)")

By convention, vertical lines indicate censored data, their corresponding x values the time at which censoring occurred.

The log-rank p-value of 0.77 indicates a non-significant result if consider p < 0.05 to indicate statistical significance. In this study, none of the duration of ART treatment were significantly superior, although Categories 1(Naive) and Categories 3(6-12 months) are doing better until end of study.

Survival Analysis Sex

Surv_ENR$SEX_E1_C2 <- factor(Surv_ENR$SEX_E1_C2 , 
                     levels = c("1", "2"), 
                     labels = c("Male", "Female"))
fit2 <- survfit(surv_object ~ SEX_E1_C2, data = Surv_ENR)
summary(fit2)
## Call: survfit(formula = surv_object ~ SEX_E1_C2, data = Surv_ENR)
## 
##                 SEX_E1_C2=Male 
##  time n.risk n.event survival std.err lower 95% CI upper 95% CI
##   383     87       1    0.989  0.0114        0.966        1.000
##   392     86       1    0.977  0.0161        0.946        1.000
##   518     84       1    0.965  0.0196        0.928        1.000
##   552     83       1    0.954  0.0226        0.910        0.999
##   708     82       1    0.942  0.0251        0.894        0.993
## 
##                 SEX_E1_C2=Female 
##  time n.risk n.event survival std.err lower 95% CI upper 95% CI
##    43     96       1    0.990  0.0104        0.969        1.000
##   274     94       1    0.979  0.0147        0.951        1.000
##   567     93       1    0.969  0.0179        0.934        1.000
##   819     92       1    0.958  0.0206        0.919        0.999
ggsurvplot(fit2, data = Surv_ENR, pval = TRUE, xlab="Duration of Study (Days)")

Similar to the previous plot, which did not indicate statistical significance, the current plot also shows a non-significant log-rank p-value of 0.63. This suggests that there are no significant differences in survival between males and females in this study.

Hazard Ratio Group of Categories and Sex

# Fit a Cox proportional hazards model
fit.coxph <- coxph(surv_object ~ Categories + SEX_E1_C2, 
                   data = Surv_ENR)
ggforest(fit.coxph, data = Surv_ENR)

Hazard ratio of 0.73 for sex groups tells that female patients have a reduced risk of dying compared to male patients (which served as a reference to calculate the hazard ratio). Using this model, tells that group of duration ART treatment and sex group does not significantly influence the patients’ risk of death in this study.